Finance

Lists
EWTX:NASDAQ
Edgewise Therapeutics Inc
$44.99
-0.73%
(-0.33) 1D
Sep 21, 1:53:18 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EWTX...
Open
$45.70
High
$45.98
Low
$44.09
Mkt. cap
4.89B
Avg. vol.
1.28M
Volume
636.54K
52-wk high
$48.50
52-wk low
$14.25
EPS
-$1.85
Beta
0.32
Shares outstanding
108.60M
No. of employees
127
Open
$45.70
High
$45.98
Low
$44.09
Mkt. cap
4.89B
Avg. vol.
1.28M
Volume
636.54K
52-wk high
$48.50
52-wk low
$14.25
EPS
-$1.85
Beta
0.32
Shares outstanding
108.60M
No. of employees
127
News stories
From web sources and news partners
About Edgewise Therapeutics Inc
CEO-
Employees127
Founded2017
HeadquartersBoulder, Colorado, United States
SectorPharmaceutical industry
Websiteedgewisetx.com
Analyst ratings
Based on 8 analysts giving stock ratings to EWTX in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for EWTX in the last 3 months.
Highest
Current $44.99
$60.00 (+33.36%)
Average
$50.63 (+12.54%)
Lowest
$36.00 (-19.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lander Egana Gorrono
H.C. Wainwright
Buy
Reiterated
$57.00
+26.7%
09/21/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$59.00
+31.1%
09/01/2026
Paul Choi
Goldman Sachs
Hold
Maintained
$36.00
-20%
08/31/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$60.00
+33.4%
08/20/2026
James Condulis
Stifel Nicolaus
Hold
Maintained
$36.00
-20%
08/11/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$55.00
+22.2%
08/07/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$45.00
+0%
08/06/2026
Mazahir Alimohamed
Oppenheimer
Buy
Initiated
$51.00
+13.4%
07/09/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$51.00
+13.4%
07/06/2026
Laura Chico
Wedbush
Buy
Maintained
$52.00
+15.6%
06/17/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
06/17/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$52.00
+15.6%
06/16/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$41.00
-8.9%
06/02/2026
Martin Auster
Raymond James
Buy
Reiterated
$66.00
+46.7%
06/01/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$20.00
-55.5%
05/11/2026
David Nierengarten
Wedbush
Buy
Maintained
$46.00
+2.2%
05/08/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$51.00
+13.4%
02/09/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.53 / -$0.47
-12.16%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
37.48M
43.59M
42.65M
47.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.38M
12.38M
11.46M
14.40M
Operating expense
46.86M
55.98M
54.12M
61.94M
Total operating expenses
46.86M
55.98M
54.12M
61.94M
Operating income
-46.86M
-55.98M
-54.12M
-61.94M
Other non operating income
-
-
-
-
EBT including unusual items
-40.67M
-50.22M
-49.01M
-57.33M
EBT excluding unusual items
-40.67M
-50.22M
-49.01M
-57.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-40.67M
-50.22M
-49.01M
-57.33M
Net profit margin
-
-
-
-
Earnings per share
-0.39
-0.47
-0.46
-0.53
Interest and investment income
6.19M
5.76M
5.10M
4.62M
Interest expense
-
-
-
-
Net interest expenses
6.19M
5.76M
5.10M
4.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.34M
-55.45M
-53.58M
-61.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps